Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for sudden sensorineural hearing loss
IRCT20110603006699N5Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of rivaroxaban in acute sensorineural hearing loss (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Pure tone audiometry level, Word recognition score and 1 more. Started Mar 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on IRCT20110603006699N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110603006699N5.